United States: The Third Circuit Gives the Green Light to RICO Plaintiffs Seeking to Recover Payments for Prescription Drugs

This week, the Third Circuit altered the legal landscape for civil Racketeer Influenced and Corrupt Organizations Act (RICO) claims against pharmaceutical companies. The ruling in In re Avandia Marketing, Sales Practices & Product Liability Litigation allows the plaintiffs' RICO claims to proceed; in their suit, the plaintiffs allege that GlaxoSmithKline LLC (GSK) engaged in a marketing campaign to minimize the side effects of Avandia, a drug prescribed to treat Type II diabetes, and thereby increase sales at a higher price than it otherwise would have been sold.

The plaintiffs alleged claims under § 1964(c) of RICO. According to the plaintiffs, GSK violated RICO by committing predicate acts of wire fraud, mail fraud, tampering with witnesses, and use of interstate facilities to conduct unlawful activity. Plaintiffs allege that GSK engaged in these predicate acts through a marketing campaign designed to boost confidence in Avandia's safety.

The plaintiffs, union welfare funds that pay for prescription coverage for their enrollees, argue that they lost money due to GSK's misrepresentations and brought the suit as a class action. As third-party payors (TPPs), the plaintiffs pay for all or some of the cost of drugs that the TPP has listed on its formulary. The formulary is comprised of drugs that have been evaluated for safety, efficacy, and cost effectiveness.

After a trial court denied GSK's motion to dismiss, the Third Circuit's ruling came as part of an interlocutory appeal on the issues of whether the plaintiffs have standing and whether the complaint adequately alleged proximate causation. The Third Circuit found in favor of the plaintiffs on both questions.

On appeal, GSK contended that the plaintiffs did not have standing because they lacked a concrete injury to business or property within the meaning of RICO. Specifically, GSK relied on the Third Circuit's decision in Maio v. AETNA, Inc. to argue that the plaintiffs' allegations were too dependent on future events, such as Avandia being unsafe or ineffective. In Maio, the Third Circuit concluded that health insurance beneficiaries could not maintain a RICO claim for economic injury against their insurer based on alleged misrepresentations regarding the services included in their HMO plans. Rejecting the plaintiffs' argument that they had paid high premiums for inferior health insurance, the Third Circuit found that the plaintiffs suffered no cognizable injury because their theory of injury was premised solely on the possibility that they might receive inadequate healthcare in the future.

Unpersuaded by GSK's analogy to Maio, the court here held that Maio was distinguishable in one crucial respect—the plaintiffs' injury was not contingent on future events. The Third Circuit held  that this case was more closely analogous to In re Warfarin Sodium Antitrust Litigation, in which TPPs alleged that the defendant violated antitrust law by spreading false information about a competitor drug, causing the TPPs to pay for the defendant's more expensive drug. In Warfarin, the Third Circuit held that TPPs do suffer a direct economic harm when, as a result of the pharmaceutical company's misrepresentation, they pay supracompetitive prices for brand name drugs. The Third Circuit extended the Warfarin court's reasoning to claims brought under RICO, finding that the TPPs adequately alleged that they had suffered direct economic harm as a result of GSK's alleged misrepresentations.

The court was unpersuaded by GSK's contention that no concrete injury existed because TPPs can anticipate fraud and, thus avoid harm by passing on that cost to their enrollees by way of higher premiums. The court noted that, at the motion to dismiss stage, no evidence supported GSK's argument and, further, the argument had no limiting principle. For example, if adopted, such a theory could be used to bar stores from recovering for shoplifting based on the presumption that their pricing model accounted for theft.

GSK also argued that the plaintiffs had not adequately alleged proximate causation because the presence of intermediaries—physicians and patients—in the causal chain rendered any harm too indirect. The court surveyed precedent on RICO causation, beginning with Holmes v. Securities Investor Protection Corp. In Holmes, the U.S. Supreme Court addressed the overbreadth concerns inherent in the language of § 1964(c) by setting out the three factors courts should assess in evaluating causation under RICO: (1) the directness of the injury; (2) the risk of multiple recoveries; and (3) the likelihood of vindication by others.

Considering these factors, the Holmes Court determined that a plaintiff-subrogee had failed to satisfy RICO's proximate cause requirement. In that case, the plaintiff alleged that the defendant manipulated a stock, which led two broker-dealers to insolvency and later required the plaintiff to reimburse the broker-dealers' customers' losses. The Court refused to find an adequate causal connection because "the link [was] too remote between the stock manipulation alleged and the customers' harm, being purely contingent on the harm suffered by the broker-dealers."

In contrast to Holmes, proximate cause will be found if a sufficiently direct relationship exists between a defendant's wrongful conduct and a plaintiff's injury. This is true even if a RICO plaintiff did not directly rely on the defendant's misrepresentation. The Third Circuit determined that proximate causation can be found where the conduct that allegedly caused the plaintiff's injuries is identical to the acts that form the basis of the RICO scheme. Further, the injury alleged by the TPPs is an economic injury independent of any physical injury suffered by Avandia users. Joining the First Circuit, the court found that doctors do not break the chain of causation because it was not the doctors' decision to prescribe Avandia that caused the plaintiffs' injuries.

Without opining on the likelihood of success of the plaintiffs' claims, the court concluded that the TPPs had adequately alleged standing and proximate causation. The court's decision adds clarity to the requirements for successfully pleading under § 1964(c) of RICO, and it may clear the way for similar litigation against pharmaceutical companies.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.